|
1
|
Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang
L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour
cell proliferation and motility by directly targeting CCNE2 in
non-small cell lung cancer. Cancer Lett. 362:208–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Facchinetti F, Marabelle A, Rossi G, Soria
JC, Besse B and Tiseo M: Moving immune checkpoint blockade in
thoracic tumors beyond non-small cell lung cancer. J Thorac Oncol.
11:1819–1836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naylor EC: Adjuvant therapy for stage I
and II non-small cell lung cancer. Surg Oncol Clin N Am.
25:585–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mburu YK, Wang J, Wood MA, Walker WH and
Ferris RL: CCR7 mediates inflammation-associated tumor progression.
Immunol Res. 36:61–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Worbs T and Förster R: A key role for CCR7
in establishing central and peripheral tolerance. Trends Immunol.
28:274–280. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hong H, He C, Zhu S, Zhang Y, Wang X, She
F and Chen Y: CCR7 mediates the TNF-α-induced lymphatic metastasis
of gallbladder cancer through the ‘ERK1/2 - AP-1’ and ‘JNK - AP-1’
pathways. J Exp Clin Cancer Res. 35:512016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Y, Liu L, Qiu X, Liu Z, Li H, Li Z, Luo
W and Wang E: CCL21/CCR7 prevents apoptosis via the ERK pathway in
human non-small cell lung cancer cells. PLoS One. 7:e332622012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X,
Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced
epithelial-mesenchymal transition and is associated with lymph node
metastasis and poor overall survival in gastric cancer. Oncotarget.
6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kallergi G, Papadaki MA, Politaki E,
Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal
transition markers expressed in circulating tumour cells of early
and metastatic breast cancer patients. Breast Cancer Res.
13:R592011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tutunea-Fatan E, Majumder M, Xin X and
Lala PK: The role of CCL21/CCR7 chemokine axis in breast
cancer-induced lymphangiogenesis. Mol Cancer. 14:352015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Zhou Y and Yang Y: CCR7 pathway
induces epithelial-mesenchymal transition through up-regulation of
Snail signaling in gastric cancer. Med Oncol. 32:4672015.PubMed/NCBI
|
|
12
|
Moschovakis GL and Förster R: Multifaceted
activities of CCR7 regulate T-cell homeostasis in health and
disease. Eur J Immunol. 42:1949–1955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saban DR: The chemokine receptor CCR7
expressed by dendritic cells: A key player in corneal and ocular
surface inflammation. Ocul Surf. 12:87–99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai W, Tao J, Zhang X, Tian X, Liu T, Feng
X, Bai J, Yan C and Han Y: Contribution of homeostatic chemokines
CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Arterioscler Thromb Vasc Biol. 34:1933–1941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mo M, Zhou M, Wang L, Qi L, Zhou K, Liu
LF, Chen Z and Zu XB: CCL21/CCR7 enhances the proliferation,
migration, and invasion of human bladder cancer T24 cells. PLoS
One. 10:e01195062015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chi BJ, Du CL, Fu YF, Zhang YN and Wang
RW: Silencing of CCR7 inhibits the growth, invasion and migration
of prostate cancer cells induced by VEGFC. Int J Clin Exp Pathol.
8:12533–12540. 2015.PubMed/NCBI
|
|
17
|
Xu Y, Liu L, Qiu X, Jiang L, Huang B, Li
H, Li Z, Luo W and Wang E: CCL21/CCR7 promotes G2/M phase
progression via the ERK pathway in human non-small cell lung cancer
cells. PLoS One. 6:e211192011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun L, Zhang Q, Li Y, Tang N and Qiu X:
CCL21/CCR7 up-regulate vascular endothelial growth factor-D
expression via ERK pathway in human non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:15729–15738. 2015.PubMed/NCBI
|
|
19
|
Wang M, Jing Y, Hu L, Gao J, Ding L and
Zhang J: Recent advances on the circadian gene PER2 and metabolic
rhythm of lactation of mammary gland. Anim Nutr. 1:257–261.
2015.doi: 10.1016/j.aninu.2015.11.008. View Article : Google Scholar
|
|
20
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016.PubMed/NCBI
|
|
21
|
Jansen VM, Mayer IA and Arteaga CL: Is
there a future for AKT inhibitors in the treatment of cancer? Clin
Cancer Res. 22:2599–2601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Tu G, Lv C, Long J, Cong L and
Han Y: Matrix metalloproteinase-9 is up-regulated by CCL19/CCR7
interaction via PI3K/Akt pathway and is involved in CCL19-driven
BMSCs migration. Biochem Biophys Res Commun. 451:222–228. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chuang CW, Pan MR, Hou MF and Hung WC:
Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated
phosphorylation and activation of Sp1 in breast cancer cells. J
Cell Physiol. 228:341–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuwabara T, Tanaka Y, Ishikawa F, Kondo M,
Sekiya H and Kakiuchi T: CCR7 ligands up-regulate IL-23 through
PI3-kinase and NF-κB pathway in dendritic cells. J Leukoc Biol.
92:309–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hollenbach M, Thonig A, Pohl S, Michel M,
Ripoll C, Greinert RA, Michl P and Zipprich A: Inflammation and
hypoxia regulate RAGE, NF-κB und pERK via glyoxalase I and
methylglyoxal in sinusoidal endothelial cells: A possible mechanism
in development of cirrhosis. Hepatology. 62:951a. 2015.
|
|
26
|
Zhao W, Sun Z, Wang S, Li Z and Zheng L:
Wnt1 participates in inflammation induced by lipopolysaccharide
through upregulating scavenger receptor A and NF-κB. Inflammation.
38:1700–1706. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cupovic J, Gil-Cruz C, Onder L,
Perez-Shibayama C, Chai Q and Ludewig B: Extra-lymphatic
CCR7-ligand expression controls virus-induced CNS inflammation.
Immunology. 140:35. 2013.
|
|
28
|
Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren
Y, Wu Y, Mei M, Zhang L and Wang X: Long non coding RNA MALAT1
promotes tumor growth and metastasis by inducing
epithelial-mesenchymal transition in oral squamous cell carcinoma.
Sci Rep. 5:159722015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu
H, Meng Q, Pang H, Chen X, Liu Y, et al: USP22 promotes tumor
progression and induces epithelial-mesenchymal transition in lung
adenocarcinoma. Lung Cancer. 88:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li F, Zou Z, Suo N, Zhang Z, Wan F, Zhong
G, Qu Y, Ntaka KS and Tian H: CCL21/CCR7 axis activating chemotaxis
accompanied with epithelial-mesenchymal transition in human breast
carcinoma. Med Oncol. 31:1802014. View Article : Google Scholar : PubMed/NCBI
|
